Systemic vasculitis associated with vemurafenib treatment: Case report and literature review

RATIONALE: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim–Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment. PATIENT CONCERNS AND DIAGNOSE: We...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Medicine (Baltimore)
Egile Nagusiak: Mirouse, Adrien, Savey, Léa, Domont, Fanny, Comarmond, Cloé, Barete, Stéphane, Plaisier, Emmanuelle, Rouvier, Philippe, Cacoub, Patrice, Saadoun, David
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer Health 2016
Gaiak:
3600
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5120889/
https://ncbi.nlm.nih.gov/pubmed/27861332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004988
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak